Auris Medical Reports Second Quarter 2018 Financial Results and Provides Business Update
August 15, 2018 06:45 ET
|
Auris Medical AG
Dosing in second Phase 1 clinical trial with intranasal betahistine nearing completion Approaching important interactions with regulatory agencies Progressing with strategic repositioning of...
Auris Medical to Report Second Quarter 2018 Financial Results and Provide Business and Update on Wednesday, August 15, 2018
August 09, 2018 08:00 ET
|
Auris Medical AG
Zug, Switzerland, August 09, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Prices $7 Million Public Offering
July 12, 2018 19:59 ET
|
Auris Medical AG
Zug, Switzerland - July 12, 2018 - Auris Medical Holding AG (Nasdaq: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Announces Publication Confirming Dose-Dependent Effects of Betahistine and Relationship to Bioavailability in Cat Model of Acute Vertigo
July 03, 2018 08:00 ET
|
Auris Medical AG
Zug, Switzerland, July 3, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and...
Auris Medical to Host Key Opinion Leader Call Focused on AM-201 Program for Treating Major Side Effects of Antipsychotics on June 11, 2018
May 30, 2018 07:45 ET
|
Auris Medical AG
Zug, Switzerland, May 30, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and...
Auris Medical Provides Business and Strategy Update and Reports First Quarter 2018 Financial Results
May 15, 2018 06:45 ET
|
Auris Medical AG
Expansion of intranasal betahistine program into mental health supportive care Initiating project AM-201 for the treatment of histaminergic receptor mediated weight gain and drowsiness in...
Auris Medical to Report First Quarter 2018 Financial Results and Provide Business and Strategy Update on Tuesday, May 15, 2018
May 14, 2018 07:30 ET
|
Auris Medical AG
Zug, Switzerland, May 14, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111
May 07, 2018 07:30 ET
|
Auris Medical AG
Design for single pivotal phase 3 trial validated by European Medicines Agency Regulatory pathway towards European market approval mapped out Strategy update scheduled together with...
Auris Medical Announces Publication Related to AM-111 in Peer-Reviewed Scientific Journal
May 04, 2018 06:45 ET
|
Auris Medical AG
Zug, Switzerland, May 4, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical Announces Early Repayment of Part of its Loan Facility
April 09, 2018 06:45 ET
|
Auris Medical AG
Zug, Switzerland, April 9, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...